Novartis Venture Fund
Profile, fund size and portfolio
Novartis Venture Fund is the corporate venture arm of Novartis AG (pharmaceuticals). It was founded in 1996 and is based in Basel, Switzerland. It invests from Seed to Series A in biotechnology, biopharma, life sciences.
Every figure links to its source
Snapshot
Data behind this graphic
The firm has not published a portfolio breakdown.
Sources: .
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 750M | Assets under management | Stated by the firm or its parent | S3 |
| Companies backed | 40+ | companies | Stated by the firm | S1 |
| Companies on the firm's portfolio page | 31 | companies | Counted from the firm's own list | S3 |
Sources: S3 Novartis Venture Fund portfolio; S1 Novartis Venture Fund home.
Where it invests and who leads it
Geography
- Headquarters
- Basel, Switzerland
- Offices
- Basel, Switzerland
- Cambridge, MA, United States
Investment regionsS3S1
- North America
- Europe
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Novartis AG | Single source | S8 |
| Parent industry | Pharmaceuticals | Single source | S8 |
| Founded | 1996 | Single source | S4 |
| Headquarters | Basel, Switzerland | Single source | S2 |
| Status | Active | Single source | S1 |
| Headline size | USD 750M (Assets under management) | Single source | S3 |
| Companies backed | 40+ | Single source | S1 |
| Stages | Seed, Series A | Single source | S3 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Price | Source |
|---|---|---|---|---|---|
| Acorda Therapeutics | IPO | 2006 | NASDAQ: ACOR | S4 | |
| Aeglea Biotherapeutics | IPO | 2016 | NASDAQ: AGLE | S4 | |
| Aerpio Therapeutics | IPO | 2017 | NASDAQ:ARPO | S4 | |
| Aileron Therapeutics | IPO | 2017 | NASDAQ | S4 | |
| Akebia Therapeutics | IPO | 2014 | NASDAQ: AKBA | S4 | |
| Akouos | IPO | 2020 | NASDAQ: AKUS | S4 | |
| Altimmune, Inc. | IPO | 2017 | NASDAQ: ALT | S4 | |
| Annexon | IPO | 2020 | NASDAQ:ANNX | S4 | |
| Adicet Bio | IPO | 2020 | NASDAQ: ACET | S4 | |
| Bicycle Therapeutics | IPO | 2019 | NASDAQ: BCYC | S4 | |
| BioNano Genomics | IPO | 2018 | NASDAQ: BNGO | S4 | |
| Celladon | IPO | 2014 | NASDAQ: CLDN | S4 | |
| Cellerix | IPO | 2011 | NYSE: TIG | S4 | |
| CombinatorRx | IPO | 2005 | NASDAQ: CRXX | S4 | |
| Cytos Biotechnology | IPO | 2002 | S4 |
For founders
Portfolio
The firm's portfolio page lists 31 companies: 31 active.S3
The firm also states 40+ companies backed. The page list and the stated total measure different things.S1
Every company on the Novartis Venture Fund list
31 companies, as listed on the firm's own website.S3 Read the firm's list.
- Amphista Therapeutics
- Anaveon
- Aravax
- Artios Pharma Limited
- Arvada Therapeutics
- AstronauTx
- Atalanta
- Averna Therapeutics
- CatalYm
- Citryll
- Enterprise Therapeutics
- Epi Biologics
- Epsilogen
- Fore Biotherapeutics
- FoRx Therapeutics
- GentiBio
- Granite Bio
- HYKU Biosciences
- Kynexis
- LoQus23
- Mediar Therapeutics
- NRG Therapeutics
- ONL Therapeutics
- Protego
- RhyGaze
- Salvina
- Seawolf
- Sidewinder Therapeutics
- SpliceBio
- Tagworks Pharmaceuticals
- Vivet Therapeutics SAS
History
- Novartis Venture Fund founded (IPO exits page: since its foundation in 1996).S4
Where sources disagree
- Headline size: We manage over USD 750 million in committed capital (home page) (S1) vs approximately USD 750 million under management (portfolio page) (S3). Same figure described as committed capital and as under management.S1S3
- Companies count: more than 40 portfolio companies (home page); over 40 (portfolio page) (S1) vs 31 company names listed on portfolio page (S3). Page lists fewer names than the stated count.S1S3
Official pages
Read the firm's own pages for current information.
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Novartis Venture Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.